Imigran Juvenil

Sumatriptan, the active ingredient in Imigran Juvenil, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a nasal spray for nasal use. It treats acute migraine attacks in adults and adolescents.\n\nGNH India supplies Imigran Juvenil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran Juvenil is a triptan that acts on the serotonin pathway to relieve migraine and related headache disorders.\n\n- Migraine: provides rapid relief of acute migraine attacks in adults and adolescents.\n- Cluster headache: offers acute treatment of episodic cluster headache attacks.\n- Migraine with aura: alleviates symptoms of migraine attacks accompanied by visual or sensory aura.

Common Side Effects:\n- Taste disturbance: altered or unpleasant taste sensation.\n- Nasal irritation: burning or stinging in the nasal passages.\n- Dizziness: feeling light‑headed or unsteady.\n- Nausea: mild stomach upset.\n\nSerious or Rare Side Effects:\n- Coronary vasospasm: chest pain due to constricted coronary arteries.\n- Stroke or transient ischemic attack: neurological deficits from reduced cerebral blood flow.\n- Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities when combined with serotonergic agents.

Before using Imigran Juvenil, consider the following precautions.\n\n- Cardiovascular assessment: evaluate history of heart disease or uncontrolled hypertension.\n- Contraindicated with MAO inhibitors: avoid use within 14 days of MAOI therapy.\n- Caution with other triptans: do not exceed recommended number of doses per month.\n- Monitor for serotonin syndrome: especially when combined with SSRIs, SNRIs, or other serotonergic drugs.\n- Store at room temperature: keep in the original package, protect from moisture and direct light.

Sumatriptan may interact with several drug classes.\n\nMajor Interactions (Avoid):\n- MAO inhibitors: increased risk of hypertensive crisis.\n- Other triptans or ergot alkaloids: additive vasoconstriction.\n- SSRIs/SNRIs: heightened potential for serotonin syndrome.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): elevated plasma concentrations.\n- Monoamine oxidase‑B inhibitors: limited data, use with caution.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may increase risk of gastrointestinal bleeding.\n- Antihypertensives: possible additive blood pressure effects.\n- Oral contraceptives: may slightly raise triptan levels.